Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation.

Life-threatening complications such as graft versus host disease and infection remain major barriers to the success of allogeneic hemopoietic stem cell transplantation (SCT). While pretransplantation conditioning and posttransplantation immunosuppression are important risk factors for infection, the reasons that similarly immunosuppressed transplant recipients show marked variation in frequency of infection after allogeneic SCT are unclear. Mannose-binding lectin (MBL) deficiency is a risk factor for infection in other situations where immunity is compromised. We investigated associations between MBL2 gene polymorphisms and risk of major infection following allogeneic SCT. Ninety-seven related allogeneic donor-recipient pairs were studied. Clinical data including survival, days of fever, graft versus host disease incidence and severity, and infection were collected by case note review. Five single-nucleotide polymorphisms in the MBL2 gene were genotyped using the polymerase chain reaction and sequence-specific primers. MBL2 coding mutations were associated with an increased risk of major infection following transplantation. This association was seen for donor (P =.002, odds ratio [OR] 4.1) and recipient (P =.04, OR 2.6) MBL2 genotype. MBL2 promoter variants were also associated with major infection. The high-producing haplotype HYA was associated with a markedly reduced risk of infection (recipient HYA P =.0001, OR 0.16; donor HYA P =.001, OR 0.23). Donor MBL2 coding mutations and recipient HYA haplotype were independently associated with infection in multivariate analysis. These results suggest that MBL2 genotype influences the risk of infection following allogeneic SCT and that both donor and recipient MBL2 genotype are important. These findings raise the possibility that MBL replacement therapy may be useful following transplantation.

[1]  N. Klein,et al.  Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study , 2001, The Lancet.

[2]  S. Thiel,et al.  Association between deficiency of mannose-binding lectin and severe infections after chemotherapy , 2001, The Lancet.

[3]  I. Weissman,et al.  Immunity to infections following hematopoietic cell transplantation. , 2001, Current opinion in immunology.

[4]  M. Loos,et al.  Differential expression of murine MBL-A and MBL-C in B cells, dendritic cells and macrophages by immunregulatory and proinflammatory cytokines , 2001 .

[5]  J. Crawford,et al.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. , 2001, The Journal of clinical investigation.

[6]  M. Melbye,et al.  Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. , 2001, JAMA.

[7]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[8]  S. Thiel,et al.  Recombinant expression of human mannan-binding lectin. , 2000, International immunopharmacology.

[9]  S. Thiel,et al.  Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. , 2000, Journal of immunological methods.

[10]  W. Thomson,et al.  Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK Caucasoids. , 2000, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[11]  J. Ferrara,et al.  Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. , 2000, Journal of hematotherapy & stem cell research.

[12]  Marshall,et al.  Mannose Binding Lectin Polymorphisms are Associated With Early Age of Disease Onset and Autoimmunity in Common Variable Immunodeficiency , 2000, Scandinavian journal of immunology.

[13]  D. Jack,et al.  Mannose-Binding Lectin Binds to a Range of Clinically Relevant Microorganisms and Promotes Complement Deposition , 2000, Infection and Immunity.

[14]  E. Montserrat,et al.  Immune Reconstitution Following Allogeneic Peripheral Blood Progenitor Cell Transplantation , 2000, Leukemia & lymphoma.

[15]  J. Feingold,et al.  Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study , 1999, BMJ.

[16]  S. Yamamoto,et al.  High-level and effective production of human mannan-binding lectin (MBL) in Chinese hamster ovary (CHO) cells. , 1999, Journal of immunological methods.

[17]  S. Chanock,et al.  Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. , 1998, The Journal of clinical investigation.

[18]  M. Turner,et al.  Mannose-binding lectin (MBL) in health and disease. , 1998, Immunobiology.

[19]  Stéfansson,et al.  Reconstitution of Opsonizing Activity by Infusion of Mannan‐Binding Lectin (MBL) to MBL‐Deficient Humans , 1998, Scandinavian journal of immunology.

[20]  M. Pembrey,et al.  Mannose-binding lectin alleles in a prospectively recruited UK population , 1997, The Lancet.

[21]  D. Coggon,et al.  Prospective cohort study of predictors of incident low back pain in nurses , 1997, BMJ.

[22]  A. Svejgaard,et al.  Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin , 1997, The Lancet.

[23]  M. Pembrey,et al.  Mannose-binding lectin alleles in a prospectively recruited UK population. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. , 1997, Lancet.

[24]  M. Turner,et al.  Mannose-binding lectin: the pluripotent molecule of the innate immune system. , 1996, Immunology today.

[25]  S. Thiel,et al.  Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. , 1995, Journal of immunology.

[26]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[27]  C. Cockerell Bacterial infections. , 1995, Journal of the International Association of Physicians in AIDS Care.

[28]  J. Summerfield,et al.  Human mannose-binding protein gene is regulated by interleukins, dexamethasone and heat shock. , 1993, The Quarterly journal of medicine.

[29]  R. Levinsky,et al.  Molecular basis of opsonic defect in immunodeficient children , 1991, The Lancet.

[30]  C. Morton,et al.  The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10 , 1989, The Journal of experimental medicine.

[31]  R. Ezekowitz,et al.  A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins [published erratum appears in J Exp Med 1991 Sep 1;174(3):753] , 1988, The Journal of experimental medicine.

[32]  M. Taylor,et al.  Mannose-binding proteins in human serum: identification of mannose-specific immunoglobulins and a calcium-dependent lectin, of broader carbohydrate specificity, secreted by hepatocytes. , 1986, Biochimica et biophysica acta.

[33]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[34]  B. Winchester,et al.  Isolation of mannose-binding proteins from human and rat liver. , 1983, The Biochemical journal.

[35]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.